• Flatiron’s high-quality real-world data and innovative artificial intelligence-based extraction are generating novel learnings on treatment safety and patterns for people with genitourinary cancers

NEW YORK: Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including three accepted abstracts for poster presentation.

“At this year’s ASCO Genitourinary Cancers Symposium, Flatiron scientists and our collaborators are using high-quality real-world data and novel AI approaches, to advance critical understanding on how real-world patients with genitourinary cancers are being treated and the effectiveness of those strategies,” said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. “By applying innovative AI and our unique expertise to our worldwide network of oncology EHR real-world data, Flatiron is answering questions on treatment patterns, efficacy, and safety with an unprecedented scale, filling evidence gaps in a rapidly evolving treatment landscape.”

Highlights include:

• a poster presentation on machine learning’s ability to investigate the real-world treatment-emergent adverse events that over 5,200 patients experience during 1L treatments for locally advanced or metastatic urothelial carcinoma
• a poster presentation identifying common real-world treatment patterns for patients diagnosed with metastatic castration-resistant prostate cancer in the community setting
• a poster presentation conducting the largest real-world analysis of sacituzumab govitecan to date, building on previously reported results of efficacy and safety in treating locally advanced/metastatic urothelial cancer

To learn more about how our real-world evidence solutions support genitourinary research, register today for “Genitourinary cancer insights: Leveraging RWE to learn from the experience of every patient,” a webinar to discuss research presented at ASCO GU, how scaled RWD can unlock biomarker-defined cohorts, and ways longitudinal patient data can provide insight into real-world treatment patterns and patient journeys.

Follow Flatiron Health on Twitter and LinkedIn for more updates on ASCO’s #GU25.

Poster Discussions and Presentations
Real-world safety of first-line therapies for locally advanced or metastatic urothelial cancer in the US
Amanda Nizam, Mairead Kearney, Seyed Hamidreza Mahmoudpour, Valerie Morris, Carroline Lobo, Jason Hoffman, Ilian IIiev
Poster Session B: Urothelial Carcinoma Track
Abstract #759
Poster Bd #E21

Real-world treatment patterns in patients diagnosed with metastatic castration-resistant prostate cancer in the US, 2018-2023
Eleni Efstathiou, Weiyan Li, Nina Yeh, Stephen Corson, Kumar Mukherjee. Chinelo Orji
Poster Session A: Prostate Cancer Track
Abstract #74
Poster Bd #B20

Retrospective, observational analysis of real-world safety outcomes in sacituzumab govitecan-treated patients with locally advanced/metastatic urothelial cancer
Mamta Parikh, Peter McMahon, Susan Eng, Freda Boateng, Youssef Ghazi, Kerstin Schmidt, Michelle Brockman, Mitch Sierecki
Poster Session B: Urothelial Carcinoma Track
Abstract #709
Poster Bd #D6

About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

Fonte: Business Wire